FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

93 letters match. Newest first.

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Zhejiang Gaorong Cosmetic Co., Ltd.

    FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.

    High risk
  3. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  4. K.C. Pharmaceuticals, Inc.

    FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.

    High risk
  5. Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd.

    Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.

    High risk
  6. Almon Healthcare Private Limited

    Almon Healthcare, an Indian active pharmaceutical ingredient (API) maker, knowingly used mislabeled, untested raw material and shipped affected drugs to the U.S.

    High risk
  7. Shimoga Chemicals

    FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.

    High risk
  8. Gopaldas Visram & Co., Ltd.

    FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.

    High risk
  9. Laboratorios Dr. Collado S.A.

    FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.

    High risk
  10. Umendra Life Sciences Private Limited

    Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.

    High risk
  11. Asanuma Corporation - Sagamihara Factory

    FDA warned Japan's Asanuma Sagamihara factory, an OTC drug maker, that its talc was never tested for asbestos.

    High risk
  12. Laboratorios Jaloma S.A. de C.V.

    FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.

    High risk
  13. Harbin Jixianglong Biotech Co., Ltd.

    FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

    High risk
  14. Hangzhou Yiqi Biotechnology Co., Ltd

    FDA cited Hangzhou Yiqi Biotechnology, an API maker in China, for four manufacturing practice failures found in a records review.

    High risk
  15. IDO Pharm Co., Ltd.

    IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.

    High risk
  16. Active Cosmetics Manufacturing Inc.

    FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.

    High risk
  17. Respilon Production S.R.O.

    FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.

    Medium
  18. Pro Numb Tattoo Numbing Spray, LLC

    FDA cited Pro Numb Tattoo Numbing Spray for selling unapproved, misbranded numbing drugs and manufacturing quality failures after a November 2025 inspection.

    High risk
  19. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.

    High risk
  20. Flowchem Pharma Private Limited

    FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.

    High risk
  21. Cosmetic Manufacturers Pty Ltd.

    FDA warned Cosmetic Manufacturers Pty Ltd. that its Australian drug site was adulterated due to CGMP violations and placed its drugs on import alert.

    High risk
  22. Absolutely Natural

    FDA warned Absolutely Natural of Melbourne, Florida, over nonprescription drug manufacturing violations, including weak contamination investigations and component testing.

    High risk
  23. Tower Laboratories Ltd.

    FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.

    High risk
  24. SV Labs Corporation

    SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.

    High risk
  25. Owen Biosciences, Inc.

    Owen Biosciences' over-the-counter benzoyl peroxide acne lotion had over 20 parts per million benzene and lacked release testing.

    High risk
  26. Cdymax India Pharma Private Limited

    FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.

    High risk
  27. Guangxi Yulin Pharmaceutical Group Co. Ltd.

    FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.

    High risk
  28. Creative Essences, Inc.

    FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.

    High risk
  29. Anhui Hanbon Daily Chemical Co., Ltd.

    FDA warns Anhui Hanbon Daily Chemical over CGMP failures in OTC drugs, including use of an incorrect excipient and untested ingredients.

    High risk
  30. Glenmark Pharmaceuticals Limited

    FDA warns Glenmark over unresolved dissolution failures and inadequate investigations at its Pithampur, India drug plant.

    High risk
  31. Healwell Homeo Private Limited

    FDA warns Healwell Homeo over pest-infested drug storage and manufacturing violations.

    High risk
  32. Amish Origins Management, LLC

    FDA warned Amish Origins over manufacturing quality failures and unapproved or misbranded OTC pain relief and lip balm products.

    High risk
  33. CTK OTC Laboratories LLC formerly FMK LABS, Inc.

    CTK OTC Laboratories, formerly FMK Labs, failed to investigate out-of-spec results and validate processes for OTC drugs, including sunscreens.

    High risk
  34. Huangshi Hygienic Material Medicine Co., Ltd.

    Huangshi Hygienic Material Medicine released U.S. drugs without identity and strength testing and lacked stability data for labeled expiration dates.

    High risk
  35. Taizhou Jingshang Cosmetics Technology Co., Ltd.

    FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.

    High risk
  36. BEO Pharma Inc. dba BEO Pharmaceuticals Inc.

    FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.

    High risk
  37. ABR Laboratory LLC

    FDA warned ABR Laboratory, a contract drug testing lab, that unverified microbial test methods and missed investigations made tested drugs adulterated.

    High risk
  38. Jagsonpal Pharmaceuticals Limited

    Jagsonpal Pharmaceuticals cited for API CGMP and listing failures after Indian inspection, leading to US import alert.

    High risk
  39. Wuhu Nuowei Chemistry Co., Ltd.

    FDA cited Wuhu Nuowei Chemistry for API CGMP deviations in impurity testing, stability data, and cleaning, and placed products on import alert.

    High risk
  40. Strukmyer LLC dba Strukmyer Medical

    Strukmyer Medical was cited for current good manufacturing practice violations after FDA found repeated microbial contamination in water used to make OTC drugs.

    High risk
  41. Sombra Cosmetics, Inc.

    FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.

    High risk
  42. Brands International Corporation

    Brands International, a Canadian drug manufacturer, limited an FDA inspection and had manufacturing quality violations including mold contamination.

    High risk
  43. Micro Orgo Chem

    Micro Orgo Chem in India failed CGMP for API drugs, including cleaning, process validation, stability and records.

    High risk
  44. WANABANA USA LLC

    WanaBana USA LLC failed to verify foreign supplier safety for lead-contaminated apple cinnamon puree pouches.

    High risk
  45. Multaler et Cie SAS

    FDA cites Multaler et Cie for manufacturing failures and unapproved sunscreen after April 2024 inspection.

    High risk
  46. Analytical Food Laboratories, Inc.

    FDA warned contract testing lab Analytical Food Laboratories after inspection found unvalidated drug test methods and weak quality oversight.

    High risk
  47. MMC Healthcare Ltd.

    FDA warned MMC Healthcare Ltd. in Chennai that its drug products violate manufacturing rules, citing backdated records, weak computer controls, and unvalidated test methods.

    High risk
  48. Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd.

    FDA warned Guangzhou Baiyunshan Jingxiutang Pharmaceutical over current good manufacturing practice violations in over-the-counter drug manufacturing, including inadequate specs and microbial testing.

    High risk
  49. Laboratorio Magnachem International

    FDA cited Laboratorio Magnachem for CGMP failures and unapproved, misbranded Broncochem cough/cold drugs after a 2023 inspection.

    High risk
  50. TCT Nutraceuticals SDN. BHD

    FDA warns TCT Nutraceuticals over manufacturing-rule failures in OTC hand sanitizer, including no methanol testing.

    High risk